# Rivastigmine in the Management of Delirium

> **NCT01487317** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 23 (actual)

## Conditions studied

- Delirium

## Interventions

- **DRUG:** Rivastigmine transdermal patch
- **DRUG:** placebo patch

## Key facts

- **NCT ID:** NCT01487317
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2015-08
- **Final completion:** 2016-02
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2016-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01487317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01487317, "Rivastigmine in the Management of Delirium". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01487317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*